Literature DB >> 27624957

Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We're Gonna Need a Bigger Boat".

Brad Spellberg1,2, Robert A Bonomo3.   

Abstract

Entities:  

Keywords:  CRE; Enterobacteriaceae; antibiotic resistance; carbapenem-resistance; ceftazidime-avibactam

Mesh：

Substances：

Year:  2016        PMID： 27624957      PMCID： PMC5146721          DOI： 10.1093/cid/ciw639

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  20 in total

1.  Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis.

Authors:  Mitchell J Schwaber; Yehuda Carmeli
Journal:  J Antimicrob Chemother       Date:  2007-09-11       Impact factor: 5.790

2.  Whither infectious diseases? Memories, manpower, and money.

Authors:  R G Petersdorf
Journal:  J Infect Dis       Date:  1986-02       Impact factor: 5.226

Review 3.  Prioritized current unmet needs for antibacterial therapies.

Authors:  B Spellberg; D Shlaes
Journal:  Clin Pharmacol Ther       Date:  2014-08       Impact factor: 6.875

Review 4.  Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis.

Authors:  Mical Paul; Adi Lador; Simona Grozinsky-Glasberg; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-01-07

5.  Amino acid substitutions at Ambler position Gly238 in the SHV-1 beta-lactamase: exploring sequence requirements for resistance to penicillins and cephalosporins.

Authors:  Andrea M Hujer; Kristine M Hujer; Marion S Helfand; Vernon E Anderson; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop.

Authors:  Marisa L Winkler; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2015-05-08       Impact factor: 5.790

7.  Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center.

Authors:  L B Rice; E C Eckstein; J DeVente; D M Shlaes
Journal:  Clin Infect Dis       Date:  1996-07       Impact factor: 9.079

Review 8.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.

Authors:  David van Duin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2016-04-20       Impact factor: 9.079

9.  Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae.

Authors:  Leanne B Gasink; Paul H Edelstein; Ebbing Lautenbach; Marie Synnestvedt; Neil O Fishman
Journal:  Infect Control Hosp Epidemiol       Date:  2009-12       Impact factor: 3.254

Review 10.  New β-lactamase inhibitors: a therapeutic renaissance in an MDR world.

Authors:  Sarah M Drawz; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2013-12-30       Impact factor: 5.191
View more
  9 in total

1.  Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N132G in the Conserved SDN Motif.

Authors:  Clément Ourghanlian; Daria Soroka; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

2.  Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.

Authors:  Ruta Petraitiene; Vidmantas Petraitis; Povilas Kavaliauskas; Bo Bo W Maung; Farehin Khan; Ethan Naing; Thein Aung; Vilma Zigmantaite; Ramune Grigaleviciute; Audrius Kucinskas; Rimantas Stakauskas; Benjamin N Georgiades; Chase A Mazur; Joshua A Hayden; Michael J Satlin; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 3.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

4.  Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the KPC-2 β-Lactamase.

Authors:  Fabrice Compain; Michel Arthur
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

5.  Survival of Carbapenem-Resistant Klebsiella pneumoniae Sequence Type 258 in Human Blood.

Authors:  Frank R DeLeo; Scott D Kobayashi; Adeline R Porter; Brett Freedman; David W Dorward; Liang Chen; Barry N Kreiswirth
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

Review 6.  Carbapenemase-Producing Organisms: A Global Scourge.

Authors:  Robert A Bonomo; Eileen M Burd; John Conly; Brandi M Limbago; Laurent Poirel; Julie A Segre; Lars F Westblade
Journal:  Clin Infect Dis       Date:  2018-04-03       Impact factor: 9.079

7.  Multidrug resistant pathogens respond differently to the presence of co-pathogen, commensal, probiotic and host cells.

Authors:  Agnes P Chan; Yongwook Choi; Lauren M Brinkac; Radha Krishnakumar; Jessica DePew; Maria Kim; Mary K Hinkle; Emil P Lesho; Derrick E Fouts
Journal:  Sci Rep       Date:  2018-06-05       Impact factor: 4.379

8.  Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering.

Authors:  Melissa D Barnes; Marisa L Winkler; Magdalena A Taracila; Malcolm G Page; Eric Desarbre; Barry N Kreiswirth; Ryan K Shields; Minh-Hong Nguyen; Cornelius Clancy; Brad Spellberg; Krisztina M Papp-Wallace; Robert A Bonomo
Journal:  MBio       Date:  2017-10-31       Impact factor: 7.867

9.  Virtual screening identifies broad-spectrum β-lactamase inhibitors with activity on clinically relevant serine- and metallo-carbapenemases.

Authors:  Francesca Spyrakis; Matteo Santucci; Lorenzo Maso; Simon Cross; Eleonora Gianquinto; Filomena Sannio; Federica Verdirosa; Filomena De Luca; Jean-Denis Docquier; Laura Cendron; Donatella Tondi; Alberto Venturelli; Gabriele Cruciani; Maria Paola Costi
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.